Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Shares of Anavex Life Sciences (AVXL) , a clinical-stage biotech making medicines to treat central nervous system (CNS) diseases, have skyrocketed 94.7% in the past three months due to recent pipeline successes.Anavex Life Sciences’ clinical developmental pipeline includes two candidates, ANAVEX 2-73 (blarcamesine) and ANAVEX 3-71. Both these candidates are being developed in separate studies across various stages of development to treat a plethora of CNS indications like Alzheimer’s disease (AD), Parkinson ...